Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline
- PMID: 26444994
- DOI: 10.1210/jc.2015-2236
Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline
Abstract
Objective: The objective of this document is to generate a practice guideline for the management and treatment of symptoms of the menopause.
Participants: The Treatment of Symptoms of the Menopause Task Force included six experts, a methodologist, and a medical writer, all appointed by The Endocrine Society.
Evidence: The Task Force developed this evidenced-based guideline using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned three systematic reviews of published data and considered several other existing meta-analyses and trials.
Consensus process: Multiple e-mail communications, conference calls, and one face-to-face meeting determined consensus. Committees of The Endocrine Society, representatives from endorsing societies, and members of The Endocrine Society reviewed and commented on the drafts of the guidelines. The Australasian Menopause Society, the British Menopause Society, European Menopause and Andropause Society, the European Society of Endocrinology, and the International Menopause Society (co-sponsors of the guideline) reviewed and commented on the draft.
Conclusions: Menopausal hormone therapy (MHT) is the most effective treatment for vasomotor symptoms and other symptoms of the climacteric. Benefits may exceed risks for the majority of symptomatic postmenopausal women who are under age 60 or under 10 years since the onset of menopause. Health care professionals should individualize therapy based on clinical factors and patient preference. They should screen women before initiating MHT for cardiovascular and breast cancer risk and recommend the most appropriate therapy depending on risk/benefit considerations. Current evidence does not justify the use of MHT to prevent coronary heart disease, breast cancer, or dementia. Other options are available for those with vasomotor symptoms who prefer not to use MHT or who have contraindications because these patients should not use MHT. Low-dose vaginal estrogen and ospemifene provide effective therapy for the genitourinary syndrome of menopause, and vaginal moisturizers and lubricants are available for those not choosing hormonal therapy. All postmenopausal women should embrace appropriate lifestyle measures.
Similar articles
-
The 2017 hormone therapy position statement of The North American Menopause Society.Menopause. 2018 Nov;25(11):1362-1387. doi: 10.1097/GME.0000000000001241. Menopause. 2018. PMID: 30358733
-
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline.J Clin Endocrinol Metab. 2016 Nov;101(11):3888-3921. doi: 10.1210/jc.2016-2118. Epub 2016 Oct 13. J Clin Endocrinol Metab. 2016. PMID: 27736313
-
An introduction to the Endocrine Society Clinical Practice Guideline on treatment of symptoms of the menopause.Post Reprod Health. 2016 Mar;22(1):6-8. doi: 10.1177/2053369115626029. Post Reprod Health. 2016. PMID: 26936942
-
Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline.J Clin Endocrinol Metab. 2014 Oct;99(10):3489-510. doi: 10.1210/jc.2014-2260. J Clin Endocrinol Metab. 2014. PMID: 25279570
-
Postmenopausal hormone therapy: an Endocrine Society scientific statement.J Clin Endocrinol Metab. 2010 Jul;95(7 Suppl 1):s1-s66. doi: 10.1210/jc.2009-2509. Epub 2010 Jun 21. J Clin Endocrinol Metab. 2010. PMID: 20566620 Free PMC article. Review.
Cited by
-
Measuring serum oestrogen levels in breast cancer survivors using vaginal oestrogens: a systematic review.Breast Cancer Res Treat. 2024 Jul;206(2):215-226. doi: 10.1007/s10549-024-07364-0. Epub 2024 May 23. Breast Cancer Res Treat. 2024. PMID: 38780887 Free PMC article.
-
Not All Maca Is Created Equal: A Review of Colors, Nutrition, Phytochemicals, and Clinical Uses.Nutrients. 2024 Feb 14;16(4):530. doi: 10.3390/nu16040530. Nutrients. 2024. PMID: 38398854 Free PMC article. Review.
-
Sex-Related Differences in Self-Reported Symptoms at Diagnosis in Pheochromocytomas and Paragangliomas.J Endocr Soc. 2024 Jan 24;8(3):bvae005. doi: 10.1210/jendso/bvae005. eCollection 2024 Jan 16. J Endocr Soc. 2024. PMID: 38313160 Free PMC article.
-
Changing Care in Changing World - Reproductive Marker of Cardiovascular Disease Risk in Women.J Midlife Health. 2023 Jul-Sep;14(3):149-151. doi: 10.4103/jmh.jmh_248_23. Epub 2023 Dec 30. J Midlife Health. 2023. PMID: 38312768 Free PMC article. No abstract available.
-
Role of menopausal hormone therapy in the prevention of postmenopausal osteoporosis.Open Life Sci. 2023 Dec 12;18(1):20220759. doi: 10.1515/biol-2022-0759. eCollection 2023. Open Life Sci. 2023. PMID: 38152576 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical